509 A phase I clinical trial of RNF43 peptide-specific immune cell therapy combined with low dose cyclophosphamide for patients with advanced solid tumors. (September 2015) - Hijikata, Y.; Okazaki, T.; Yamada, K.; Tani, K.; Murahashi, M.; Ogata, H.